Skip to search formSkip to main contentSkip to account menu

Proprotein Convertase Subtilisin/Kexin Type 9 Measurement

Known as: PCSK9, Proprotein Convertase Subtilisin/Kexin 9 
The determination of the proprotein convertase subtilisin/kexin type 9 present in a sample.
National Institutes of Health

Related topics

Related topics

4 relations
CDISC SDTM Laboratory Test Terminology by CodeCDISC SDTM Laboratory Test Terminology by NameClinical Data Interchange Standards Consortium TerminologyPCSK9 gene

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Effect of an RNAi therapeutic targeting PCSK9 on atherogenic lipoproteins: Pre-specified secondary endpoints in orion 1
Review
2013
Review
2013
PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia
The atherogenic dyslipidemia is a pathophysiological lipid triad, composed of high triglycerides and low-density lipoprotein and… 
2013
2013
Mutation in the PCSK9 Gene in Omani Arab Subjects with Autosomal Dominant Hypercholesterolemia and its Effect on PCSK9 Protein Structure.
Proprotein convertase subtilisin/kexin type (PCSK9) is a crucial protein in LDL cholesterol (LDL-C) metabolism by virtue of its… 
2012
2012
Genetic susceptibility for coronary heart disease and type 2 diabetes complications.
Type II diabetes (T2D)3 represents a major public health challenge, with the WHO having estimated a current prevalence of 346… 
2008
2008
A PCSK9 variant and familial combined hyperlipidaemia
Background: Our discovery in 2003 of the first mutations of PCSK9 gene causing autosomal dominant hypercholesterolaemia (ADH… 
2008
2008
Genome‐wide expression analysis of cells expressing gain of function mutant D374Y‐PCSK9
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of serum cholesterol. The possibility that PCSK9 also… 
2008
2008
Deletion (1)(p32.2–p32.3) detected by array‐CGH in a patient with developmental delay/mental retardation, dysmorphic features and low cholesterol: A new microdeletion syndrome?
We report on a 25‐year‐old male with mental retardation and global developmental delay, low levels of total and LDL cholesterol… 
2007
2007
Secreted PCSK 9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protease that regulates low density lipoprotein receptor (LDLR… 
Highly Cited
2004
Highly Cited
2004
Genetic variants in PCSK9 affect the cholesterol level in Japanese
AbstractMutations in the proprotein convertase subtilisin/kexin 9 (PCSK9) gene have been reported in affected members of two… 
2004
2004
The mystery of PCSK9.
Many of the most important breakthroughs in science do not come from hypothesis-driven experiments. Apart from serendipity… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)